Lars Ostergaard (31 results)

Condition: New.

Condition: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Condition: As New. Unread book in perfect condition.

Condition: New.

Condition: New.

Condition: New.

Condition: As New. Unread book in perfect condition.

Condition: New. Print on Demand.

Condition: New.

Condition: New. Alison M. Smith is an Emeritus Fellow and former Group Leader at the John Innes Centre, Norwich, UK. She has a PhD in Plant Sciences from the University of Cambridge. Her research interest is in plant metabolism, particularly the central roles of starch .

HRD. Condition: New. New Book. Shipped from UK. Established seller since 2000.

Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Paperback. Condition: Brand New. 582 pages. 11.00x8.25x10.98 inches. In Stock.

Condition: New. pp. 368.

Condition: New. pp. 368.

Buch. Condition: Neu. Neuware -Trends and challenges in one of the key areas of contemporary drug development - presented by industry professionals from leading pharmaceutical companies. 304 pp. Englisch.

Buch. Condition: Neu. Neuware -Trends and challenges in one of the key areas of contemporary drug development - presented by industry professionals from leading pharmaceutical companies. 304 pp. Englisch.

Condition: New.

Buch. Condition: Neu. Neuware -Drug discovery strategies for next-generation anti-diabetic and anti-obesity therapies Diabetes ranks as the seventh leading cause of death globally, claiming 1.5 million victims annually, yet the complexity of energy metabolism makes pharmaceutical intervention difficult-often requiring simultaneous modulation of multiple drug targets. Trends in Drug Discovery in Diabetes and Obesity assembles drug developers from pharma companies who share hard-to-find insight on strategies for developing more efficient therapies. The book surveys critical drug classes including GLP-1 receptor agonists, GIP antagonists, poly-agonist drugs, and long-acting insulin variants, covering both peptide and small molecule approaches. Selected case studies detail the discovery pathways of recently approved drugs, providing direct insight into the decision-making and optimization processes that led from target identification through clinical validation to market approval. Readers will also find: - Reviews of recent therapy developments and emerging treatment paradigms reshaping the current diabetes and obesity pharmacological landscape- Evaluation of poly-agonist drug potential and their projected role in future multi-target therapeutic strategies for metabolic disorders- Perspectives from industry professionals across pharmaceutical companies offering practical context rarely available in academic literature alone- Coverage of peptide drug design strategies alongside small molecule approaches for addressing complex metabolic pathway modulation challenges- Case studies tracing recently approved drugs from early discovery through optimization, illustrating real-world drug development decision frameworks Designed for medicinal chemists, pharmaceutical chemists, and endocrinologists working in drug discovery and development, this volume delivers the strategic and mechanistic insight needed to advance the next generation of therapeutics targeting diabetes and obesity across both industry and academic research settings.…

Condition: New. pp. 368.

Buch. Condition: Neu. Trends in Drug Discovery in Diabetes and Obesity | Lars Linderoth (u. a.) | Buch | Trends in Drug Discovery | 304 S. | Englisch | 2026 | Wiley-VCH GmbH | EAN 9783527353309 | Verantwortliche Person für die EU: Wiley-VCH GmbH, Boschstr. 12, 69469 Weinheim, product-safety[at]wiley[dot]com | Anbieter: preigu. …

Hardcover. Condition: Brand New. 304 pages. 6.69x0.59x9.61 inches. In Stock.

Buch. Condition: Neu. Neuware - Trends and challenges in one of the key areas of contemporary drug development - presented by industry professionals from leading pharmaceutical companies.

Buch. Condition: Neu. Neuware -Drug discovery strategies for next-generation anti-diabetic and anti-obesity therapies Diabetes ranks as the seventh leading cause of death globally, claiming 1.5 million victims annually, yet the complexity of energy metabolism makes pharmaceutical intervention difficult-often requiring simultaneous modulation of multiple drug targets. Trends in Drug Discovery in Diabetes and Obesity assembles drug developers from pharma companies who share hard-to-find insight on strategies for developing more efficient therapies. The book surveys critical drug classes including GLP-1 receptor agonists, GIP antagonists, poly-agonist drugs, and long-acting insulin variants, covering both peptide and small molecule approaches. Selected case studies detail the discovery pathways of recently approved drugs, providing direct insight into the decision-making and optimization processes that led from target identification through clinical validation to market approval. Readers will also find: - Reviews of recent therapy developments and emerging treatment paradigms reshaping the current diabetes and obesity pharmacological landscape- Evaluation of poly-agonist drug potential and their projected role in future multi-target therapeutic strategies for metabolic disorders- Perspectives from industry professionals across pharmaceutical companies offering practical context rarely available in academic literature alone- Coverage of peptide drug design strategies alongside small molecule approaches for addressing complex metabolic pathway modulation challenges- Case studies tracing recently approved drugs from early discovery through optimization, illustrating real-world drug development decision frameworks Designed for medicinal chemists, pharmaceutical chemists, and endocrinologists working in drug discovery and development, this volume delivers the strategic and mechanistic insight needed to advance the next generation of therapeutics targeting diabetes and obesity across both industry and academic research settings.Wiley-VCH GmbH, Boschstraße 12, 69469 Weinheim 304 pp. Englisch.…

Condition: As New. Unread book in perfect condition.

Condition: As New. Unread book in perfect condition.

Condition: New. Alison M. Smith is an Emeritus Fellow and former Group Leader at the John Innes Centre, Norwich, UK. She has a PhD in Plant Sciences from the University of Cambridge. Her research interest is in plant metabolism, particularly the central roles of starch .

Condition: New.

Condition: New.

Buch. Condition: Neu. Neuware -Drug discovery strategies for next-generation anti-diabetic and anti-obesity therapies Diabetes ranks as the seventh leading cause of death globally, claiming 1.5 million victims annually, yet the complexity of energy metabolism makes pharmaceutical intervention difficult-often requiring simultaneous modulation of multiple drug targets. Trends in Drug Discovery in Diabetes and Obesity assembles drug developers from pharma companies who share hard-to-find insight on strategies for developing more efficient therapies. The book surveys critical drug classes including GLP-1 receptor agonists, GIP antagonists, poly-agonist drugs, and long-acting insulin variants, covering both peptide and small molecule approaches. Selected case studies detail the discovery pathways of recently approved drugs, providing direct insight into the decision-making and optimization processes that led from target identification through clinical validation to market approval. Readers will also find: - Reviews of recent therapy developments and emerging treatment paradigms reshaping the current diabetes and obesity pharmacological landscape- Evaluation of poly-agonist drug potential and their projected role in future multi-target therapeutic strategies for metabolic disorders- Perspectives from industry professionals across pharmaceutical companies offering practical context rarely available in academic literature alone- Coverage of peptide drug design strategies alongside small molecule approaches for addressing complex metabolic pathway modulation challenges- Case studies tracing recently approved drugs from early discovery through optimization, illustrating real-world drug development decision frameworks Designed for medicinal chemists, pharmaceutical chemists, and endocrinologists working in drug discovery and development, this volume delivers the strategic and mechanistic insight needed to advance the next generation of therapeutics targeting diabetes and obesity across both industry and academic research settings. 304 pp. Englisch.…